JP2023166387A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166387A5
JP2023166387A5 JP2023129964A JP2023129964A JP2023166387A5 JP 2023166387 A5 JP2023166387 A5 JP 2023166387A5 JP 2023129964 A JP2023129964 A JP 2023129964A JP 2023129964 A JP2023129964 A JP 2023129964A JP 2023166387 A5 JP2023166387 A5 JP 2023166387A5
Authority
JP
Japan
Prior art keywords
synthetic
sulfated
alkyl
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023129964A
Other languages
English (en)
Japanese (ja)
Other versions
JP7702454B2 (ja
JP2023166387A (ja
Filing date
Publication date
Priority claimed from JP2019549419A external-priority patent/JP7330893B2/ja
Application filed filed Critical
Publication of JP2023166387A publication Critical patent/JP2023166387A/ja
Publication of JP2023166387A5 publication Critical patent/JP2023166387A5/ja
Application granted granted Critical
Publication of JP7702454B2 publication Critical patent/JP7702454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023129964A 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 Active JP7702454B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762469643P 2017-03-10 2017-03-10
US62/469,643 2017-03-10
JP2019549419A JP7330893B2 (ja) 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
PCT/US2018/021986 WO2018165656A1 (en) 2017-03-10 2018-03-12 Short-acting heparin-based anticoagulant compounds and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019549419A Division JP7330893B2 (ja) 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Publications (3)

Publication Number Publication Date
JP2023166387A JP2023166387A (ja) 2023-11-21
JP2023166387A5 true JP2023166387A5 (cg-RX-API-DMAC7.html) 2024-03-22
JP7702454B2 JP7702454B2 (ja) 2025-07-03

Family

ID=63449042

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019549419A Active JP7330893B2 (ja) 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
JP2023129964A Active JP7702454B2 (ja) 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019549419A Active JP7330893B2 (ja) 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Country Status (5)

Country Link
US (2) US11903963B2 (cg-RX-API-DMAC7.html)
EP (1) EP3579897A4 (cg-RX-API-DMAC7.html)
JP (2) JP7330893B2 (cg-RX-API-DMAC7.html)
CN (2) CN116622006B (cg-RX-API-DMAC7.html)
WO (1) WO2018165656A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
CA3126805A1 (en) 2019-01-15 2020-07-23 Optimvia, Llc Engineered aryl sulfate-dependent enzymes
AU2020310172A1 (en) 2019-07-09 2022-03-03 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
US20250154290A1 (en) * 2022-02-17 2025-05-15 Kyushu University, National University Corporation Recombinant heparin-like substance and method for producing the same
CN115417937B (zh) * 2022-08-12 2023-06-06 山东大学 一种含双抗凝血酶结合序列的肝素十二糖及其制备方法与应用
CN116120484B (zh) * 2022-09-01 2024-11-08 山东大学 一种抗凝血肝素寡糖苯联二聚体及其制备方法与应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸6−o−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 2−o−硫酸基転移酵素
CA2233343A1 (en) 1995-09-29 1997-04-03 Biomarin Pharmaceutical, Inc. Use of heparinases to decrease inflammatory responses
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US7307159B2 (en) 2001-05-08 2007-12-11 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase from P. multocida and methods of making and using same
IL127851A0 (en) 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US7034006B2 (en) 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CN100369925C (zh) 2000-07-07 2008-02-20 生化学工业株式会社 透明质酸低聚糖级分及含有该物质的药品
CA2441984A1 (en) 2001-03-28 2002-10-10 Massachusetts Institute Of Technology Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
WO2004005475A2 (en) 2002-07-05 2004-01-15 University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
AU2003262794A1 (en) 2002-08-23 2004-03-11 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20040259142A1 (en) 2003-06-04 2004-12-23 Imperial College Innovations Limited Products and methods
EP1529785B1 (en) 2003-10-24 2011-03-16 3M Innovative Properties Company Aqueous dispersions of polytetrafluoroethylene particles
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
US7619637B2 (en) 2004-04-09 2009-11-17 Samsung Electronics Co., Ltd. Systems and methods for improved gamut mapping from one image data set to another
EP1761550A2 (en) 2004-05-26 2007-03-14 California Institute of Technology Small molecule stimulators of neuronal growth
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006015171A2 (en) 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
EP1885865A4 (en) * 2005-05-12 2010-12-22 Univ North Carolina ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES
US8129148B2 (en) 2005-08-24 2012-03-06 Seikagaku Corporation Process for preparation of chondroitin fraction
AU2007267561B2 (en) 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US20090035787A1 (en) 2007-07-23 2009-02-05 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
EP2234669A4 (en) 2007-12-21 2011-11-23 Glycan Biosciences DESIGN AND SELECTION OF MEDICAMENTS FOR MODULATING THE FUNCTION AND ACTIVITY OF INTERLEUKIN 13
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
US8993536B2 (en) 2009-02-02 2015-03-31 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
MX2011010616A (es) 2009-04-09 2012-03-14 Univ North Carolina Metodos para tratar edema relacionado a isquemia-reperfusion.
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
DK2646037T3 (en) 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
WO2012088416A2 (en) 2010-12-23 2012-06-28 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
JP6670235B2 (ja) 2013-06-17 2020-03-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 可逆的ヘパリン分子、その製法及びその使用方法
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
JP7670561B2 (ja) 2021-06-28 2025-04-30 日本航空電子工業株式会社 コネクタ

Similar Documents

Publication Publication Date Title
US5380716A (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
JP3345020B2 (ja) 合成ポリサッカライド、それらの製造法およびそれらを含む医薬組成物
JP2016523535A5 (cg-RX-API-DMAC7.html)
Li et al. Heparosan‐Derived Heparan Sulfate/Heparin‐Like Compounds: One Kind of Potential Therapeutic Agents
JP2020510119A5 (cg-RX-API-DMAC7.html)
JP3594990B2 (ja) 3−デオキシオリゴ糖、その製造方法およびそれを含有する医薬組成物
Jin et al. Preactivation-based, iterative one-pot synthesis of anticoagulant pentasaccharide fondaparinux sodium
TW580391B (en) Sulfated oligosaccharides having anticoagulant/antithrombotic activity
CN105504097A (zh) 一种硫酸化肝素寡糖及其制备方法和应用
JP2019501263A (ja) 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用
JP3929486B2 (ja) 脱硫酸化多糖の製造法及び脱硫酸化ヘパリン
JP4695756B2 (ja) 新規な五糖類、その製造法およびそれを含む医薬組成物
EP2356128A1 (en) Oligosaccharide compounds for use in mobilising stem cells
WO1992018546A1 (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US20100075922A1 (en) Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof
JPH11513061A (ja) 合成ポリサッカライド、それらの製造法およびそれらを含む医薬組成物
JP4587148B2 (ja) 平滑筋細胞増殖促進剤
WO2005092348A1 (ja) ヘパリン様オリゴ糖含有hgf産生促進薬剤
Wessel Heparinoid mimetics
US7285536B2 (en) Anti-cancer therapeutic compounds
EP1694714B1 (en) Low molecular weight polysaccharides having antithrombotic activity
US6329351B1 (en) Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
RU2176915C2 (ru) Полусинтетические сульфаминогепаросансульфаты, имеющие высокую антиметастатическую активность и пониженный геморрагический риск
JP5153324B2 (ja) 硬組織形成促進剤
AU706002B2 (en) New anticoagulants